GSK4108771A

GSK4108771A is an experimental mRNA-based vaccine candidate designed for the prevention or treatment of herpes simplex virus type 2 (HSV-2) infections. Developed by GSK, initially in collaboration with CureVac, the vaccine utilizes messenger RNA technology to instruct host cells to express specific HSV-2 viral antigens. This expression is intended to trigger a robust immune response, including the production of neutralizing antibodies and the activation of T-cells, to provide protection against genital herpes. As of 2024, GSK4108771A is in Phase 1 clinical development, where its safety, reactogenicity, and immunogenicity are being evaluated in healthy participants. This candidate is part of GSK's broader strategy to leverage mRNA platforms for challenging viral targets, following the company's acquisition of full rights to the program from CureVac in mid-2024.

Other names

GSK HSV mRNA vaccineGSK herpes simplex virus type 2 vaccine